Physician profile

Jeffrey Neu

Pulmonary Disease · Williamsville, NY

NPI 1184608911

$19,946.20

in general payments reported to CMS, 2019-2025

47 companies · $3,423 in 2025

The $3,423 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

See the full distribution for Pulmonary Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$9,108.37
Education$244.09

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $3,072.41 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Astrazeneca Pharmaceuticals LP $2,684.99 2019-2025 Airsupra, Tezspire, Fasenra
Boehringer Ingelheim Pharmaceuticals, INC. $2,569.08 2019-2025 Ofev, Spiriva Respimat, Stiolto Respimat
Actelion Pharmaceuticals US, INC. $2,305.49 2019-2025 Uptravi, Opsumit
Grifols USA, LLC $1,350.97 2019-2025 Prolastin-C Liquid
Genzyme Corporation $889.75 2019-2025
Electromed, INC. $744.72 2019-2025 Smartvest
Regeneron Healthcare Solutions, INC. $652.46 2019-2025 Dupixent
Takeda Pharmaceuticals U.S.A., INC. $619.70 2020-2025 Glassia, Cuvitru
Mylan Specialty L.P. $560.68 2019-2024 Yupelri
Bayer Healthcare Pharmaceuticals INC. $460.13 2019-2024
Insmed, INC. $394.81 2019-2025 Arikayce, Brinsupri
Genentech USA, INC. $334.04 2019-2023 Xolair
Mallinckrodt Hospital Products INC. $300.17 2020-2025 Acthar
Inogen, INC. $265.66 2022-2025 Inogen One G5 Oxygen Concentrator - Bluetooth
Show all 47 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $236.07 2021-2025 Tezspire
Philips North America LLC $213.57 2019-2023
Merck Sharp & Dohme LLC $213.19 2023-2025 Winrevair, Zerbaxa
Verona Pharma, INC. $211.77 2025 Ohtuvayre
Allergan, INC. $210.72 2019-2020
Viatris Specialty LLC $176.48 2025 Yupelri
Gilead Sciences, INC. $157.03 2019-2021
Teva Pharmaceuticals USA, INC. $142.63 2019-2022
Covis Pharma Gmbh $110.99 2020-2022
Jazz Pharmaceuticals INC. $106.60 2019-2020
Abbvie INC. $97.71 2021-2024
Sanofi-Aventis U.S. LLC $88.99 2025
Nabriva Therapeutics, Plc $74.08 2020-2021
Pfizer INC. $72.21 2022-2025
Mallinckrodt Enterprises LLC $70.33 2019
Shire North American Group INC $55.62 2019
Circassia INC. $55.54 2019
Axsome Therapeutics, INC. $43.74 2023 Sunosi
Baxter Healthcare $43.60 2023 Hillrom - Life 2000 Ventilation System
Idorsia Pharmaceuticals US INC $40.09 2024 Quviviq
3b Medical, INC. $35.95 2024 Luna
United Therapeutics Corporation $35.87 2021-2022
Optinose US, INC. $34.74 2020-2024
Sunovion Pharmaceuticals INC. $33.18 2019
Harmony Biosciences LLC $28.21 2025
Pharming Healthcare, INC. $26.19 2025 Ruconest
Liquidia Technologies, INC. $25.87 2025 Yutrepia
Novartis Pharmaceuticals Corporation $24.24 2019
Janssen Pharmaceuticals, INC $20.26 2022-2023
Pulmonx Corporation $18.93 2024 Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter
Paratek Pharmaceuticals, INC. $18.61 2019
Eisai INC. $18.13 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jeffrey Neu

$19,946.20

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $3,423 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/7751/jeffrey-neu

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.